The molecule that runs everything
NAD+ — nicotinamide adenine dinucleotide — is not optional. The practitioner corpus describes it as the substrate without which the electron transport chain refuses to catalyze. Picture a union worker on strike holding a sign that reads "No NAD+, no ATP." That's the literal biochemistry. Glycolysis breaks glucose down into pyruvate and generates a small amount of ATP. That pyruvate gets shuttled into the mitochondria, runs through the Krebs cycle, and produces NADH — the reduced form of NAD+, carrying two electrons. NADH then delivers those electrons to Complex I of the inner mitochondrial membrane. The electrons cascade through Complexes I → III → IV, pumping protons across the membrane, building the gradient that drives ATP synthase. In the free pool of a healthy cell, you want roughly a 700:1 ratio of NAD+ to NADH. Drop that ratio and the cascade stalls — there's no oxidized NAD+ available to pick up the next electron from the next round of substrate breakdown.
Three things consume NAD+, and all three escalate with age. Sirtuins — SIRT1 through SIRT7 — are NAD+-dependent deacetylases. They strip acetyl groups off histones, which winds chromatin back up and silences gene transcription, protecting DNA from damage. SIRT3 is the mitochondrial sirtuin and is particularly load-bearing for cellular energy as you age. Sirtuins only function in the presence of NAD+. No NAD+, no deacetylation, no chromatin protection, accelerated epigenetic drift. PARP — poly-ADP-ribose polymerase, now sometimes called ARTD — fires every time a single-strand DNA break happens. It physically marks the damage site and pulls in repair machinery. Each PARP activation consumes NAD+ directly. As DNA damage accumulates with age, PARP activity escalates, and NAD+ gets drained faster than the salvage pathway can replace it. CD38 is the third consumer and arguably the worst. CD38 is a NADase expressed on inflammatory macrophages, and its activity goes up with age, with chronic inflammation, and with oxidative stress. The practitioner corpus is explicit: inflammation increases CD38, CD38 consumes NAD+, lower NAD+ impairs sirtuin and PARP function, and the cell loses both its energy substrate and its repair machinery in the same loop. This is the inflammatory aging spiral at the molecular level.
Why this collapses the entire system
When NAD+ runs out, three failures stack on top of each other. First, ATP production drops. The electron transport chain can't run uncoupled — it needs the constant electron handoff from NADH, and NADH needs to be regenerated by NAD+ accepting electrons elsewhere. By age 70, mitochondrial ATP output has declined by roughly 50% in typical adults, per the practitioner consensus. Your cells are not making the energy they need to do their jobs. Second, DNA repair throttles down. PARP can't fire without NAD+. Single-strand breaks accumulate. Genomic instability rises. The practitioner corpus is clear that animals genetically deficient in PARP show massive tissue injury — meaning when you're functionally PARP-deficient because there's no NAD+ for it to use, you get the same cascade. Third, sirtuins go silent. Chromatin opens up that shouldn't be open. Inflammatory gene expression rises. Mitochondrial biogenesis — controlled in large part by SIRT3 and the PGC-1α master regulator pathway — stops. You lose your ability to make new mitochondria to replace the dying ones. Senescent cells accumulate. Tissue function degrades.
This is what people are actually feeling when they describe "low energy after 40," "brain fog," "can't recover from workouts," "sleep stopped working." It's not a hormone problem first. It's not a thyroid problem first. It's the molecular substrate of energy production running dry, and every downstream system — hormones, cognition, recovery, immunity — losing the ATP budget it needs to operate.
The Phase 1 NAD+ restoration stack (Weeks 1-4)
This chapter is mechanism-first; the full week-by-week protocol comes in Module 3. But the substrate is consistent enough on the core stack that the table belongs here as orientation:
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| NAD+ (injectable) | 100-200 mg | Subcutaneous | 3-5x/week | 🟢 Expert | Direct NAD+ restoration. Substrate describes injection as the route that bypasses oral absorption limits. Start low — flushing/chest pressure common at higher doses. |
| NMN (oral precursor) | 250-500 mg | Oral, AM | Daily | 🟢 Expert | Salvage pathway substrate. Practitioner consensus is NMN crosses into the salvage pool and supports baseline NAD+ levels between injections. |
| Methylene Blue | 0.5-1 mg | Oral, AM | Daily, cycle 5 on / 2 off | 🟣 Experimental | Substrate describes MB as an alternative electron carrier that supports the electron transport chain when NADH delivery is impaired. Start at 0.5 mg; only increase if no effect at 5 days. Never exceed 1 mg without supervision. |
| MOTS-c | 5-10 mg | Subcutaneous | 2-3x/week | 🟢 Expert | Mitochondrially-encoded peptide. Activates AMPK, stimulates mitochondrial biogenesis. Pairs with NAD+ restoration by building the machinery the restored NAD+ will run through. |
| SS-31 (Elamipretide) | [practitioner corpus thin on specific dose for this protocol — track and report] | Subcutaneous | — | 🟣 Experimental | Cardiolipin-targeting peptide. Stabilizes the inner mitochondrial membrane where the electron transport chain lives. |
What's NOT happening yet (Weeks 1-4)
- You are not "boosting" anything. You are refilling a substrate that has been chronically depleted. The first 2-3 weeks are repayment of a deficit, not net gain.
- NAD+ levels in blood are not a clean read. The practitioner corpus is explicit that the meaningful pool is intracellular, particularly in mitochondria, and serum NAD+ does not reliably track tissue NAD+. Don't chase a blood number.
- NAD+ restoration may not help senescent cells — and could in theory feed CD38-driven inflammation in tissue with high inflammatory macrophage burden. The substrate flags this as a real consideration: if your inflammatory load is high, restoring NAD+ without addressing the CD38 source can propagate the inflammation it's meant to resolve. This is why Phase 2 of the path addresses CD38 modulation directly.
- Energy will not feel "clean" immediately. Flushing on NAD+ injections is common. Some people feel wired-then-crashed in the first week as mitochondrial metabolism reorganizes. The clean energy lift is a Week 3-4 phenomenon, not a Day 3 phenomenon.
- This is not a cognitive enhancer in the nootropic sense. Methylene blue at 0.5-1 mg supports the ETC. It does not "boost focus" the way stimulants do. If you're expecting Adderall-shaped effects you'll mis-read the signal.
The corpus describes NAD+ collapse as the upstream lever. Run the stack. Track ATP-dependent outputs — recovery, sleep architecture, training capacity — not the molecule itself.